NCT01044433 · OUTCOME

Disease Control Rate

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck · Source last updated 2020-03-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage
Interval / dispersion: 90% Confidence Interval
Time frame: 5 years

Groups in this outcome

Arm I

Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14. lapatinib ditosylate: Given orally capecitabine: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I	44

Reported measurements

Source class 1

Values in percentage · Interval/dispersion: 90% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Arm I	68	Not reported	55	80	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
55
upper Limit
80
value
68

denoms

counts
group Id
OG000
value
44
units
Participants

dispersion Type

90% Confidence Interval

groups

description
Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14. lapatinib ditosylate: Given orally capecitabine: Given orally
id
OG000
title
Arm I

param Type

NUMBER

reporting Status

POSTED

time Frame

5 years

title

Disease Control Rate

type

SECONDARY

unit Of Measure

percentage

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice